Melbourne, VIC, Australia; New Haven, CT, USA, Jan. 12, 2022 (GLOBE NEWSWIRE) -- Cogstate (ASX.CGS), via its global commercial partner Eisai Co., Ltd, is pleased to announce that Cogstate technology ...

Clinical research and health tech companies Medidata and Cogstate are joining forces to speed up trials and improve outcomes measurement across diseases of the central nervous system, the partners ...

BOSTON--(BUSINESS WIRE)--The cognitive science company, Cogstate, today announced that its Healthcare Division has received CE Mark approval for its Cognigram TM digital cognitive assessment system.

Japanese pharma Eisai is boosting its 2019 pact with Australian medtech firm Cogstate and its cognitive function test. The original pact, penned last August, was a development and sales deal centered ...

Biopharma sponsors and CROs now have access to a modern eCOA solution that seamlessly integrates a configurable, no-code platform with validated cognitive assessments and deep clinical expertise ...

Melbourne, Oct. 01, 2020 (GLOBE NEWSWIRE) -- Neuroscience technology company, Cogstate Ltd (ASX.CGS), announced today the appointment of Chris Edgar, PhD as Chief Science Officer and Prof. Paul Maruff ...

NEW HAVEN, Conn.--(BUSINESS WIRE)--The cognitive science company, Cogstate Ltd (ASX:CGS) today announced it has been chosen as the preferred provider to the global healthcare leader, Eli Lilly and ...

Eisai Co., Ltd. and Cogstate, Ltd. announced that the companies have entered into a collaboration whereby Eisai has secured the global development rights and exclusive commercialization rights of all ...

PERTH, Australia – Neuroscience technology company Cogstate Ltd. and Japanese pharmaceutical company Eisai Co. Ltd. signed a deal under which Eisai will have global development rights and exclusive ...